Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab beta + tislelizumab with concurrent chemoradiotherapy in unresectable locally advanced ESCC (CTC-uLAESCC)
ChiCTR2500107755Phase 2Not yet recruiting
- Sponsor
- Chongqing Qianjiang Central Hospital
- Start
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, tislelizumab and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chongqing Qianjiang Central Hospital. Primary endpoint: Complete remission rate by CT/MRI. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
cetuximabtislelizumabcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500107755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107755.